Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
转移性乳腺癌 APOBEC 突变的诊断和治疗
基本信息
- 批准号:10237883
- 负责人:
- 金额:$ 43.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-13 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntiviral AgentsAromatase InhibitorsBenchmarkingBiochemistryBioinformaticsBiological AssayBiological MarkersBiological ModelsBreast Cancer ModelBreast Cancer cell lineBreast Cancer therapyCDK4 geneCancer ModelCaringCause of DeathCell Cycle InhibitionCell LineCellsCessation of lifeCharacteristicsClinicClinicalClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsComparative Genomic AnalysisDNA RepairDNA Sequence AlterationDataData SetDependenceDetectionDevelopmentDiagnosisDiseaseDisease ResistanceDisseminated Malignant NeoplasmDrug CombinationsDrug resistanceERBB2 geneESR1 geneEndocrineEnzymesEstrogen AntagonistsEstrogen ReceptorsEstrogen receptor positiveEstrogensFAT geneFamilyGenesGeneticGenetic TranscriptionGenomic InstabilityGenomicsGlareImmune responseImmunohistochemistryImmunologicsIndividualKineticsKnock-outLarge-Scale SequencingLinkMalignant NeoplasmsMediatingMedicalMetastatic breast cancerMethodsMinorityModelingMutagenesisMutationNF1 geneNeoplasm MetastasisNewly DiagnosedPathogenesisPathogenicityPatientsPatternPhenotypePositioning AttributePrevalencePrimary NeoplasmProcessRB1 geneRecurrenceRegimenResistanceResistance developmentSamplingSeriesShapesSystemic TherapyTamoxifenTestingTherapeuticTimeTranslatingUnited StatesWomanacquired drug resistancebasebreast cancer diagnosiscancer cellcancer genomecancer therapycell free DNAchromatin remodelingcurative treatmentsdeprivationgenomic profileshormone therapyimmune checkpoint blockadeinhibitor/antagonistinnovationinsightknock-downmalignant breast neoplasmmortalitymultimodalityneoplastic cellnovel strategiesoverexpressionpatient derived xenograft modelpreventrefractory cancerresistance alleleresistance mutationtherapeutic targettranscription factortumortumor DNAtumor progression
项目摘要
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
Summary: Although the majority of early stage estrogen receptor (ER)-positive breast cancers are cured
through multimodality care, metastatic ER-positive breast cancer remains a lethal disease. Insights into this
discrepancy have come through comparative genomic analyses of primary and metastatic tumors. We and
others have identified several mutations affecting specific genes that are more prevalent in metastatic cancers
than in their primary counterparts, including ESR1, ERBB2, and NF1. These mutations result in resistance to
front-line endocrine treatments that are the mainstay systemic therapy in ER-positive breast cancer. Even
more striking than such individual mutations, however, has been the finding that certain `mutational signatures'
are enriched in metastatic disease as compared to primary breast cancers. These mutational signatures
represent the DNA damage and repair processes that shape the cancer genome and can give rise to such
mutations and the transformed phenotypes they convey. A glaring and consistent finding from multiple large-
scale sequencing studies has been that the APOBEC mutational signature is both enriched and highly
prevalent in ER-positive metastatic disease, comprising the dominant mutational signature for these drug-
resistant and ultimately lethal cancers. Our preliminary data confirm that APOBEC activation can promote the
development of endocrine resistance in ER-positive cancer models and is associated with characteristic
APOBEC-mutational changes in many drug resistance alleles. Together, these results point to the APOBEC
mutational process as a key driver in the development and pathogenesis of ER-positive metastatic breast
cancer and endocrine therapy resistance. In this highly collaborative and innovative project, we propose three
specific aims to advance the APOBEC mutational process as a biomarker and therapeutic target in breast
cancer. (1) We will develop and utilize robust bioinformatic methods to detect the presence and the timing of
onset of the APOBEC mutational signature from clinical NGS datasets of both tumor and cell free DNA
(cfDNA). We will further ascertain if a promising IHC assay for the A3B enzyme can identify those ER-positive
cancers likely to subsequently develop an APOBEC mutational signature. (2) We will determine the
mechanisms and kinetics of APOBEC's contribution to endocrine resistance. We will use isogenic cell line
models and patient derived xenografts to dissect the types of resistance patterns that are caused by APOBEC
as well their timing and whether the endocrine therapy itself contributes to the induction of APOBEC activity.
(3) We will assess both immunologic and synthetic lethal approaches to targeting tumors in which APOBEC
activity is induced and determine their capabilities in killing APOBEC-positive cancers. We anticipate that our
findings will uniquely position our team to launch clinical trials testing specific approaches to diagnose
APOBEC-positive tumors, to prevent the development of resistance to endocrine therapies, and to target the
largest subset of ER-positive endocrine-resistant metastatic breast cancers.
转移性乳腺癌中APOBEC诱变的诊断和治疗
摘要:尽管大多数早期雌激素受体(ER) - 阳性乳腺癌均已治愈
通过多模式护理,转移性ER阳性乳腺癌仍然是致命的疾病。对此有所了解
差异是通过对原发性和转移性肿瘤的比较基因组分析得出的。我们和
其他人已经确定了几个影响特定基因的突变,这些突变在转移性癌症中更为普遍
比在其主要对应物中,包括ESR1,ERBB2和NF1。这些突变导致对
前线内分泌疗法是ER阳性乳腺癌的主要系统治疗。甚至
然而,比某些“突变签名”的发现更加惊人
与原发性乳腺癌相比,在转移性疾病中富集。这些突变标志
表示塑造癌症基因组的DNA损伤和修复过程,并可能引起这种情况
它们传达的突变及其转变的表型。从多个大的
比例测序研究是APOBEC突变特征既丰富又高度
在ER阳性转移性疾病中普遍存在,包括这些药物的主要突变特征
抗性,最终致命的癌症。我们的初步数据证实,Apobec激活可以促进
ER阳性癌症模型中内分泌耐药性的发展,与特征有关
许多药物抗性等位基因的APOBEC突破性变化。这些结果在一起指向Apobec
突变过程是ER阳性转移性乳房发育和发病机理的关键驱动力
癌症和内分泌疗法耐药性。在这个高度协作和创新的项目中,我们提出了三个
具体旨在将APOBEC突变过程作为乳腺癌的生物标志物和治疗靶标发展
癌症。 (1)我们将开发并利用强大的生物信息学方法来检测存在和时间
来自肿瘤和无细胞DNA的临床NGS数据集的APOBEC突变特征的发作
(CFDNA)。我们将进一步确定A3B酶的有希望的IHC分析是否可以识别那些ER阳性
随后可能会开发APOBEC突变签名的癌症。 (2)我们将确定
Apobec对内分泌抗性的贡献的机制和动力学。我们将使用同源细胞系
模型和患者衍生的异种移植物,以剖析由APOBEC引起的电阻模式的类型
他们的时间以及内分泌疗法本身是否有助于诱导APOBEC活性。
(3)我们将评估靶向肿瘤的免疫学和合成致命方法
诱导活动并确定其杀死Apobec阳性癌症的能力。我们预计我们的
调查结果将独特地定位我们的团队启动临床试验测试特定诊断方法
APOBEC阳性肿瘤,以防止对内分泌疗法的抗性发展,并针对
ER阳性内分泌抗性转移性乳腺癌的最大子集。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarat Chandarlapaty其他文献
Sarat Chandarlapaty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarat Chandarlapaty', 18)}}的其他基金
HER2-mediated delivery of cytotoxic agents in solid tumors
实体瘤中 HER2 介导的细胞毒药物递送
- 批准号:
10381517 - 财政年份:2021
- 资助金额:
$ 43.65万 - 项目类别:
HER2-mediated delivery of cytotoxic agents in solid tumors
实体瘤中 HER2 介导的细胞毒药物递送
- 批准号:
10608129 - 财政年份:2021
- 资助金额:
$ 43.65万 - 项目类别:
Defining the impact of mutant oncogene zygosity
定义突变癌基因接合性的影响
- 批准号:
10582527 - 财政年份:2020
- 资助金额:
$ 43.65万 - 项目类别:
Defining the impact of mutant oncogene zygosity
定义突变癌基因接合性的影响
- 批准号:
10362576 - 财政年份:2020
- 资助金额:
$ 43.65万 - 项目类别:
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
转移性乳腺癌 APOBEC 突变的诊断和治疗
- 批准号:
10478015 - 财政年份:2020
- 资助金额:
$ 43.65万 - 项目类别:
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
转移性乳腺癌 APOBEC 突变的诊断和治疗
- 批准号:
10704108 - 财政年份:2020
- 资助金额:
$ 43.65万 - 项目类别:
Defining mechanisms of resistance to hormonal therapy in breast cancer
乳腺癌激素治疗耐药机制的定义
- 批准号:
10533264 - 财政年份:2018
- 资助金额:
$ 43.65万 - 项目类别:
Defining mechanisms of resistance to hormonal therapy in breast cancer
乳腺癌激素治疗耐药机制的定义
- 批准号:
10304866 - 财政年份:2018
- 资助金额:
$ 43.65万 - 项目类别:
Defining mechanisms of resistance to hormonal therapy in breast cancer
乳腺癌激素治疗耐药机制的定义
- 批准号:
10054178 - 财政年份:2018
- 资助金额:
$ 43.65万 - 项目类别:
Therapeutic approaches to ER mutant breast cancer
ER突变乳腺癌的治疗方法
- 批准号:
9238168 - 财政年份:2017
- 资助金额:
$ 43.65万 - 项目类别:
相似国自然基金
核苷类抗病毒药物嵌合型核酸纳米载体的构筑及其抗病毒性能研究
- 批准号:52303174
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向病毒核衣壳蛋白质相分离的抗病毒药物发现及机制研究
- 批准号:82302491
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
水环境中抗病毒药物及其转化副产物的识别及生态毒性效应研究
- 批准号:52300245
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
猴痘病毒入侵融合复合物、DNA聚合酶复合物的结构解析以及抗病毒药物的开发
- 批准号:82241081
- 批准年份:2022
- 资助金额:65.00 万元
- 项目类别:专项项目
CCHFV的致病机理及抗病毒药物研究
- 批准号:U22A20336
- 批准年份:2022
- 资助金额:255.00 万元
- 项目类别:联合基金项目
相似海外基金
Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV
将 HIV 特异性 CAR T 细胞靶向肠道以实现 HIV 的持久缓解
- 批准号:
10527172 - 财政年份:2023
- 资助金额:
$ 43.65万 - 项目类别:
Application of New Tools for Probing the Roles of Sphingolipids and Cholesterol in Influenza Virus Infection
应用新工具探索鞘脂和胆固醇在流感病毒感染中的作用
- 批准号:
10678459 - 财政年份:2023
- 资助金额:
$ 43.65万 - 项目类别:
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 43.65万 - 项目类别:
IAS 2023, the 12th IAS Conference on HIV Science, Brisbane, Australia, and virtually, 23-26 July 2023
IAS 2023,第 12 届 IAS HIV 科学会议,澳大利亚布里斯班,虚拟会议,2023 年 7 月 23-26 日
- 批准号:
10696505 - 财政年份:2023
- 资助金额:
$ 43.65万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 43.65万 - 项目类别: